Markus Metzler
Expertise in
8
conditions

Markus Metzler

Erlangen, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Erlangen, BY, DE 

Overview

Markus Metzler practices practicing medicine in Erlangen, Germany.

Mr. Metzler is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Ewing Sarcoma, Leukemia, Osteosarcoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 178 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Erlangen, BY, Germany
Other Locations
Germany
Regensburg, BY, Germany
Karlsruhe, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide, Methotrexate, Prednisolone, Vincristine
Study Phase: Phase 3
View 2 Less Clinical Trial

177 Total Publications

Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk.
Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk.
Journal: medRxiv : the preprint server for health sciences
Published: February 23, 2026

Frequently Asked Questions about Markus Metzler

Is Markus Metzler a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Markus Metzler is classified as an Distinguished expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Markus Metzler participate in research or clinical trials?

Yes. Markus Metzler has published 177 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Markus Metzler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Metzler's expertise for a condition
ConditionClose
    View All 50 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile